

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 10, 2016**

---

**TOKAI PHARMACEUTICALS, INC.**

(Exact Name of Company as Specified in Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-36620**  
(Commission  
File Number)

**20-1000967**  
(IRS Employer  
Identification No.)

**255 State Street, 6th Floor**  
**Boston, Massachusetts 02109**  
(Address of Principal Executive Offices) (Zip Code)

**Company's telephone number, including area code: (617) 225-4305**

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

- (b) On October 10, 2016, Timothy J. Barberich notified Tokai Pharmaceuticals, Inc. (the “Company”) of his resignation as a member of the board of directors of the Company and the compensation, audit and nominating and corporate governance committees thereof, effective immediately. Mr. Barberich’s decision to resign did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**TOKAI PHARMACEUTICALS, INC.**

Date: October 12, 2016

By: /s/ John S. McBride

John S. McBride

Chief Financial Officer and Chief Operating Officer